Last reviewed · How we verify
Matching placebo to dapagliflozin
Matching placebo to dapagliflozin is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development.
This is a matching placebo control arm, not an active drug; it contains no pharmacologically active ingredient.
At a glance
| Generic name | Matching placebo to dapagliflozin |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
In this Phase 3 trial, a placebo matching dapagliflozin's appearance and administration schedule is used as the control arm to assess the efficacy and safety of dapagliflozin (an SGLT2 inhibitor) versus inert treatment. The placebo itself has no mechanism of action.
Approved indications
Common side effects
Key clinical trials
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (PHASE3)
- Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (PHASE3)
- Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity (PHASE2)
- A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. (PHASE2)
- STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease (PHASE3)
- Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin (PHASE3)
- Dapagliflozin in Active Lupus Nephritis (PHASE4)
- A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching placebo to dapagliflozin CI brief — competitive landscape report
- Matching placebo to dapagliflozin updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI